Who Exports Cyclophosphamide from India — 259 Suppliers Behind a $19.5M Market
India's cyclophosphamide export market is supplied by 259 active exporters who collectively shipped $19.5M across 2,113 shipments. CIPLA LIMITED leads with a 42.9% market share, followed by EUGIA PHARMA SPECIALITIES LIMITED and ALEMBIC PHARMACEUTICALS LIMITED. The top 5 suppliers together control 85.0% of total export value, reflecting a concentrated market structure.
Top Cyclophosphamide Exporters from India — Ranked by Export Value
CIPLA LIMITED is the leading cyclophosphamide exporter from India, holding a 42.9% share of the $19.5M market across 2,113 shipments from 259 exporters. The top 5 suppliers — CIPLA LIMITED, EUGIA PHARMA SPECIALITIES LIMITED, ALEMBIC PHARMACEUTICALS LIMITED, VENUS REMEDIES LIMITED, SP ACCURE LABS PRIVATE LIMITED — collectively control 85.0% of total export value, indicating a highly concentrated market. Individual shares are: CIPLA LIMITED (42.9%), EUGIA PHARMA SPECIALITIES LIMITED (33.8%), ALEMBIC PHARMACEUTICALS LIMITED (4.4%), VENUS REMEDIES LIMITED (2.5%), SP ACCURE LABS PRIVATE LIMITED (1.4%).
Top Cyclophosphamide Exporters from India
Ranked by export value · 259 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | CIPLA LIMITED CYCLOPHOSPHAMIDE INJECTION CONCENTRATE 200 MG/ML ,CYCLOPHOSPHAMIDE INJECTION 200MG/ML -US ) (6960X | $8.3M | 1 | 42.9% |
| 2 | EUGIA PHARMA SPECIALITIES LIMITED CYCLOPHOSPHAMIDE INJECTION CONCENTRATE 200 MG/ML ,CYCLOPHOSPHAMIDE INJECTION 200MG/ML -US ) (6960X | $6.6M | 1 | 33.8% |
| 3 | ALEMBIC PHARMACEUTICALS LIMITED CYCLOPHOSPHAMIDE INJECTION CONCENTRATE 200 MG/ML ,CYCLOPHOSPHAMIDE INJECTION 200MG/ML -US ) (6960X | $850.4K | 1 | 4.4% |
| 4 | VENUS REMEDIES LIMITED CYCLOPHOSPHAMIDE FOR INJECTION USP 1GCYCLOPHOSPHAMIDE FOR INJECTION USP 1G (CYCLOPHOSPHAMIDE FOR INJECTION 500MG BN. | $492.4K | 5 | 2.5% |
| 5 | SP ACCURE LABS PRIVATE LIMITED CYCLOPHOSPHAMIDE INJECTION CONCENTRATE 200 MG/ML ,CYCLOPHOSPHAMIDE INJECTION 200MG/ML -US ) (6960XCYCLOPHOSPHAMIDE FOR INJECTION BP 1000MG | $272.7K | 5 | 1.4% |
| 6 | GETWELL PHARMACEUTICALS CYTOACE- 500 MG CYCLOPHOSPHAMIDE FOR INGLOTOXAN 500MG (CYCLOPHOSPHAMIDE FOR INJGLOTOXAN-500MG (CYCLOPHOSPHAMIDE FOR INJ | $241.8K | 9 | 1.2% |
| 7 | KWALITY PHARMACEUTICALS LIMITED CYCLOPHOSPHAMIDE FOR INJECTION BP 1000MGCYCLOPHOSPHAMIDE FOR INJECTION BP (BATCHCYCLOPHOSPHAMIDE FOR INJECTION BP | $235.6K | 4 | 1.2% |
| 8 | VAMA LIFECARE PRIVATE LIMITED CYATA CYCLOPHOSPHAMIDE 500MG/V AC-MEXPONFECYC 200MG INJECTION VLSCYCLOPHOSPHAMIDE INJ IP 500MG | $204.4K | 6 | 1.1% |
| 9 | 3S CORPORATION CYCLOPHOSPHAMIDE INJ IP 500MGCYCLOPHOSPHAMIDE INJECTION IP 1 GCYCLOPHOSPHAMIDE INJECTION IP 1000 MG | $171.1K | 5 | 0.9% |
| 10 | VIVALIA REMEDIES PRIVATE LIMITED CYCLOFOSFAN-GETWELL (CYCLOPHOSPHAMIDE FO | $147.8K | 1 | 0.8% |
| 11 | GETWELL PHARMA INDIA PRIVATE LIMITED CYTOACE- 500 MG CYCLOPHOSPHAMIDE FOR INGLOTOXAN 500MG (CYCLOPHOSPHAMIDE FOR INJGLOTOXAN-500MG (CYCLOPHOSPHAMIDE FOR INJ | $139.9K | 13 | 0.7% |
| 12 | GLS PHARMA LIMITED CYATA CYCLOPHOSPHAMIDE 500MG/V AC-MEXPONFECYC 200MG INJECTION VLSPONFECYC 500MG INJECTION VLS | $120.3K | 5 | 0.6% |
| 13 | UNITED BIOTECH PRIVATE LIMITED | $110.4K | 9 | 0.6% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Cyclophosphamide exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| CIPLA LIMITED | Warning Letter (November | Unknown | Unknown | Not verified | Received FDA warning letter for CGMP violations at Indore facility. |
| EUGIA PHARMA SPECIALITIES LIMITED | Warning Letter (August 20 | Unknown | Unknown | Not verified | Received FDA warning letter for CGMP violations at Unit III facility. |
| ALEMBIC PHARMACEUTICALS LIMITED | Approved | Unknown | Unknown | 223 | Received multiple FDA approvals; cumulative ANDA approvals reached 223 by 2025. |
| KWALITY PHARMACEUTICALS LIMITED | Unknown | Yes | Yes | Not verified | Holds WHO-GMP and EU-GMP certifications. |
| INTAS PHARMACEUTICALS LIMITED | Approved | Unknown | Yes | Not verified | EU-GMP certified; launched biosimilar Filgrastim in Europe in 2015. |
TransData Nexus reviewed the regulatory standing of 5 leading Cyclophosphamide exporters from India. 2 hold US FDA facility approvals, 1 maintain WHO-GMP certification, and 2 are EU GMP compliant. 2 suppliers have received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Cyclophosphamide sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," hosts a significant number of pharmaceutical manufacturing units. The region's infrastructure supports large-scale production of active pharmaceutical ingredients (APIs), including cytotoxic drugs like Cyclophosphamide. Companies such as EUGIA PHARMA SPECIALITIES LIMITED, a major exporter of Cyclophosphamide, are based in this cluster, leveraging Hyderabad's robust ecosystem for bulk drug manufacturing.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. Alembic Pharmaceuticals, headquartered in Vadodara, is among the top exporters of Cyclophosphamide, contributing 4.4% to the total exports. The region's emphasis on formulation development complements the bulk drug production capabilities of other clusters, facilitating a comprehensive supply chain for Cyclophosphamide.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a pivotal export gateway for pharmaceutical products. CIPLA LIMITED, headquartered in Mumbai, is the leading exporter of Cyclophosphamide, accounting for 42.9% of total exports. The region's proximity to major ports and well-established logistics infrastructure enhances the efficiency of Cyclophosphamide exports, particularly to the United States.
4Baddi-Nalagarh — Tax Incentive Zone
The Baddi-Nalagarh region in Himachal Pradesh has attracted numerous pharmaceutical companies due to favorable tax incentives. While specific data on Cyclophosphamide production in this cluster is limited, the region's overall contribution to India's pharmaceutical output suggests potential involvement in its manufacturing.
5Sourcing Recommendations
- Diversify Supplier Base: Given the high concentration of Cyclophosphamide exports among a few suppliers, consider engaging with multiple manufacturers to mitigate supply risks.
- Evaluate Supplier Capabilities: Assess the manufacturing capabilities and regulatory compliance of potential suppliers, focusing on those with established export records to the United States.
- Leverage Regional Strengths: Align sourcing strategies with the strengths of each pharmaceutical cluster, such as bulk drug production in Hyderabad and formulation expertise in Ahmedabad-Vadodara.
- Monitor Regulatory Approvals: Stay informed about regulatory approvals and certifications of suppliers to ensure compliance with international standards, particularly for exports to the United States.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Cyclophosphamide exporters from India
Cipla Limited and Eugia Pharma Specialties Ltd. — Theravance Biopharma sues generic companies over YUPELRI patents
Theravance Biopharma filed patent infringement lawsuits against several generic pharmaceutical companies, including Cipla Limited and Eugia Pharma Specialties Ltd., in response to their abbreviated new drug applications (ANDAs) for a generic version of YUPELRI. - IMPACT: Potential legal challenges may affect Cipla's and Eugia's focus on Cyclophosphamide exports.
Impact: Potential legal challenges may affect Cipla's and Eugia's focus on Cyclophosphamide exports.
Venus Remedies Limited — Venus Remedies secures GMP renewal from Ukraine's SMDC
Venus Remedies announced the renewal of its Good Manufacturing Practice (GMP) certification from Ukraine's State Medical Drug Control (SMDC) for its manufacturing facility, covering cephalosporin, carbapenem, and oncology injectables. - IMPACT: Enhanced regulatory compliance may bolster Venus Remedies' Cyclophosphamide export capabilities.
Impact: Enhanced regulatory compliance may bolster Venus Remedies' Cyclophosphamide export capabilities.
Alembic Pharmaceuticals Limited — Alembic Pharmaceuticals acquires 100% stake in Aleor Dermaceuticals
Alembic Pharmaceuticals completed the acquisition of Aleor Dermaceuticals Ltd., consolidating its position in the dermatology segment. - IMPACT: The acquisition may allow Alembic to reallocate resources, potentially impacting Cyclophosphamide export operations.
Impact: The acquisition may allow Alembic to reallocate resources, potentially impacting Cyclophosphamide export operations.
Common Questions — Cyclophosphamide Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which cyclophosphamide supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, CIPLA LIMITED leads with 11 recorded shipments worth $8.3M. EUGIA PHARMA SPECIALITIES LIMITED (22 shipments) and ALEMBIC PHARMACEUTICALS LIMITED (30 shipments) are also established high-volume exporters.
Q How many cyclophosphamide manufacturers are there in India?
India has 259 active cyclophosphamide exporters with a combined export market of $19.5M across 2,113 shipments to 114 countries. The top 5 suppliers hold 85.0% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for cyclophosphamide from India?
Average FOB unit price: $3.27 per unit, ranging from $0.01 to $1399.87. Average shipment value: $9.2K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 259 verified Indian exporters of Cyclophosphamide ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 2,113 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 114 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
2,113 Verified Shipments
259 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists